• Users Online: 112
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2015  |  Volume : 2  |  Issue : 2  |  Page : 7-15

The relation between interleukin-6 and different categories of acute coronary syndrome


1 Department of Cardiology and Angiology, Faculty of Medicine, University of Alexandria, Alexandria, Egypt
2 Department of Critical Care Medicine, Faculty of Medicine, University of Alexandria, Alexandria, Egypt

Correspondence Address:
Atef Abdel Aziz Mahrous
Lecturer of Critical Care Medicine, Faculty of Medicine, University of Alexandria, 66 Masged Badr st from Moustafa Kamel sr, Sidi Bishr, Alexandria
Egypt
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/2356-9115.161311

Rights and Permissions

Background Inflammation is now recognized to play a key role in the pathogenesis of atherosclerotic cardiovascular disease. Two circulating markers of inflammation, C-reactive protein (CRP) and interleukin (IL)-6, have emerged as predictors of future cardiovascular pathology and mortality in epidemiologic studies of (middle aged women) midlife healthy men and women, postmenopausal women, and older adults. The aim of the present study was to study the changes in IL-6 in acute coronary syndrome (ACS) and to clarify whether IL-6 release is a factor initiating the inflammatory process in ACS or whether it is predominantly a response to this clinical condition, and to assess its correlation with CRP, cardiac biomarkers troponin I, and CK-MB for risk prediction in ACS. Patients and methods The study included 60 patients admitted by ACS who were categorized randomly into three groups: group I included 20 patients admitted for unstable angina, group II included 20 patients admitted for ST-segment elevation myocardial infarction with successful thrombolytic therapy, and group III included 20 patients admitted for ST-segment elevation myocardial infarction with failed thrombolytic therapy. The study also included 12 healthy control patients matched for age and sex (group IV). Blood levels of IL-6, CRP, and cardiac troponin I were measured; all samples of groups II and III were obtained after thrombolytic therapy whereas samples of group I were obtained on admission. Results IL-6 was significantly higher in group II, with a mean of 87.10, and ranged from 3.0 to 550.0; on exclusion of two patients who had an IL-6 level of 220 and 550 we obtained a mean of 54. In group III, the mean level was 52.36, ranging from 5.0 to 120.0, compared with control group IV, in which it ranged from 3.0 to 5.0, mean 3.67 (P < 0.001*). There was a positive correlation between IL-6 and CRP levels in group I (r = 0.385, P = 0.094) and group II (r = 0.166, P = 0.483), but this was statistically nonsignificant, and in group III, there was a statistically significant correlation (r = 0.638, P = 0.0002). IL-6 serum levels did not correlate with cardiac troponin levels in any of the patient groups I (r = 0.049, P = 0.836), in group II (r = 0.151, P = 0.524), and in group III (r = 0.079, P = 0.741). IL-6 did not correlate with any of the risk factors such as history of IHD, HTN, DM, and smoking. There was no statistically significant correlation between IL-6 and complications, except for the development of shock. The CRP level was significantly increased in ACS in comparison with the control group. CRP showed a significant increase in group III, ranging from 10.70 to 181, mean 84.25, and ranging from 2.47 to 155, mean 54.37 in group II compared with a mean level of 50.44 in group I and a mean of 1.96 in the control group, group IV (P = 0.0001*). Conclusion Atherosclerosis is currently considered a systemic inflammatory disease and IL-6 is an inflammatory cytokine. The IL-6 serum level was significantly increased in patients with ACS and in patients with successful thrombolytic therapy. There was a statistically significant positive correlation between IL-6 and CRP in ACS patients with failed thrombolytic therapy; IL-6 serum levels did not correlate with cardiac troponin levels in any of the ACS patient groups.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed370    
    Printed7    
    Emailed0    
    PDF Downloaded87    
    Comments [Add]    
    Cited by others 1    

Recommend this journal